Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.

被引：1

作者：

Fizazi, Karim

Tran, Namphuong

Fein, Luis Enrique

Matsubara, Nobuaki

Bjartell, Anders

Galli, Luca

Lee, Jae-Lyun

Mazhar, Danish

North, Scott A.

Olmos, David

Suttmann, Henrik

Zou, Qing

Li, Susan

Martin, Jason L.

Park, Youn C.

Sulur, Giri

Deprince, Kris

De Porre, Peter

Chi, Kim N.

机构：

[1] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France

[2] Janssen Res & Dev LLC, Los Angeles, CA USA

[3] Inst Oncol Rosario, Rosario, Argentina

[4] Natl Canc Ctr Hosp East, Chiba, Japan

[5] Lund Univ, Malmo, Sweden

[6] Azienda Ospedaliero Univ Pisana, Ist Toscano Tumori, Pisa, Italy

[7] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[8] Addenbrookes Hosp, Cambridge, England

[9] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[10] Spanish Natl Canc Res Ctr, Madrid, Spain

[11] Urol Hamburg, Hamburg, Germany

[12] Nanjing Med Univ, Affiliated Canc Hosp Jiangsu Prov, Nanjing, Peoples R China

[13] Janssen Res & Dev LLC, Spring House, PA USA

[14] Janssen Res & Dev LLC, High Wycombe, Bucks, England

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Janssen Res & Dev BE, Beerse, Belgium

[17] BC Canc Agcy, Vancouver, BC, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.182

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

182

引用

页数：2

共 50 条

[1] Subsequent treatment after abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.
Chi, Kim N.
Namphuong Tran
Feyerabend, Susan
Matsubara, Nobuaki
Ozguroglu, Mustafa
Fein, Luis Enrique
Antolin, Alfredo Rodriguez
Alekseev, Boris Yakovlevich
Sulur, Giri
Protheroe, Andrew
De Porre, Peter
Li, Susan
Park, Youn C.
Mundle, Suneel
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.
Fizazi, Karim
Feyerabend, Susan
Matsubara, Nobuaki
Ozguroglu, Mustafa
Fein, Luis Enrique
Antolin, Alfredo Rodriguez
Alekseev, Boris Yakovlevich
Sulur, Giri
Protheroe, Andrew
De Porre, Peter
Li, Susan
Park, Youn C.
Mundle, Suneel
Tran, Namphuong
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Early PSA decline as a predictor of progression in patients with metastatic castration-naive prostate cancer (mCNPC) treated with abiraterone acetate and prednisone (AA/P).
Barata, Pedro C.
Sheng, Iris Yeong-Fung
Fallah, Jaleh
Gupta, Ruby
Li, Hong
Allman, Kimberly D.
Martin, Allison
Ornstein, Moshe Chaim
Gilligan, Timothy D.
Rini, Brian, I
Garcia, Jorge A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naive prostate cancer
Spetsieris, Nicholas
Boukovala, Myrto
Alafis, Ioannis
Davis, John
Zurita, Amado
Wang, Xuemei
Tu, Shi-Ming
Chapin, Brian F.
Aparicio, Ana
Corn, Paul
Wang, Jennifer
Subudhi, Sumit K.
Araujo, John
Papadopoulos, John
Pruitt, Lisa
Weldon, Justin A.
Logothetis, Christopher J.
Efstathiou, Eleni
EUROPEAN JOURNAL OF CANCER, 2021, 157 : 259 - 267
[5] Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naive prostate cancer (mCNPC).
Feyerabend, Susan
Saad, Fred
Li, Tracy
Ito, Tetsuro
Diels, Joris
Van Sanden, Suzy
De Porre, Peter
Abogunrin, Seye
Koufopoulou, Maria
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[6] Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE
Li, Tracy
Franco-Villalobos, Conrado
Proskorovsky, Irina
Sorensen, Sonja, V
Tran, NamPhuong
Sulur, Giri
Chi, Kim N.
CANCER, 2019, 125 (04) : 626 - 632
[7] Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)
Woo, H.
Fizaz, K.
Sulur, G.
Tran, N.
Fein, L.
Matsubara, N.
Rodriguez-Antolin, A.
Alekseev, B.
Ozguroglu, M.
Ye, D.
Feyerabend, S.
Protheroe, A.
Li, S.
Luna, Y.
Mundle, S.
Chi, K.
BJU INTERNATIONAL, 2019, 123 : 27 - 28
[8] Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).
Fizazi, Karim
Namphuong Tran
Fein, Luis Enrique
Matsubara, Nobuaki
Antolin, Alfredo Rodriguez
Ozguroglu, Mustafa
Ye, Dingwei
Feyerabend, Susan
Protheroe, Andrew
Sulur, Giri
Luna, Yesenia
Li, Susan
Mundle, Suneel
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[9] Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
Chi, Kim N.
Protheroe, Andrew
Rodriguez-Antolin, Alfredo
Facchini, Gaetano
Suttman, Henrik
Matsubara, Nobuaki
Ye, Zhangqun
Keam, Bhumsuk
Damiao, Ronaldo
Li, Tracy
McQuarrie, Kelly
Jia, Bin
De Porre, Peter
Martin, Jsaon
Todd, Mary B.
Fizazi, Karim
LANCET ONCOLOGY, 2018, 19 (02): : 194 - 206
[10] Medical resource utilization (MRU) of abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy (ADT) in metastatic castration-naive prostate cancer: Results from LATITUDE.
Li, Tracy
Franco-Villalobos, Conrado
Proskorovsky, Irina
Sorensen, Sonja V.
Tran, Namphuong
Sulur, Giri
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)

← 1 2 3 4 5 →